PRESS RELEASE published on 03/11/2026 at 13:30, 6 months 13 days ago NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete NanoViricides, Inc. announces completion of manufacture for NV-387 Oral Gummies clinical trial. President to present at NIBA conference. Lead drug NV-387 to target various viral infections NanoViricides NV-387 Clinical Trial Antiviral NIBA Conference
BRIEF published on 02/12/2026 at 14:35, 7 months 12 days ago NanoViricides dépose une demande de désignation de médicament orphelin pour le NV-387 dans le traitement de la MPox. NanoViricides NV-387 Désignation De Médicament Orphelin Demande Auprès De La FDA Traitement MPox
BRIEF published on 02/12/2026 at 14:35, 7 months 12 days ago NanoViricides Files Orphan Drug Application for NV-387 as MPox Treatment NanoViricides NV-387 Orphan Drug Designation FDA Application MPOX Treatment
PRESS RELEASE published on 02/12/2026 at 14:30, 7 months 12 days ago MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides NanoViricides files Orphan Drug Designation application with US FDA for NV-387 as treatment for MPox, a contagious disease with potential global pandemic threat NanoViricides NV-387 Orphan Drug Designation Mpox US FDA
BRIEF published on 02/10/2026 at 14:35, 7 months 14 days ago NanoViricides Pursues Orphan Drug Designation for Measles Treatment NanoViricides NV-387 FDA Approval Orphan Drug Designation Measles Treatment
BRIEF published on 02/10/2026 at 14:35, 7 months 14 days ago NanoViricides sollicite la désignation de médicament orphelin pour le traitement de la rougeole NanoViricides NV-387 Désignation De Médicament Orphelin Approbation De La FDA Traitement De La Rougeole
PRESS RELEASE published on 02/10/2026 at 14:30, 7 months 14 days ago Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides NanoViricides files for Orphan Drug Designation for NV-387 as Measles treatment with potential FDA incentives. Strong in vivo activity against Measles shown in humanized animal model study NanoViricides NV-387 Orphan Drug Designation Measles Treatment FDA Incentives
BRIEF published on 02/02/2026 at 14:35, 7 months 22 days ago NanoViricides Showcases Antiviral Advancements with NV-387 NanoViricides NV-387 Clinical Trials Antiviral Therapy Broad-spectrum
BRIEF published on 02/02/2026 at 14:35, 7 months 22 days ago NanoViricides présente des avancées antivirales avec le NV-387 NanoViricides NV-387 Essais Cliniques À Large Spectre Thérapie Antivirale
PRESS RELEASE published on 02/02/2026 at 14:30, 7 months 22 days ago NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres NanoViricides, Inc. announces President Dr. Anil R. Diwan's interview on Mission Matters Podcast discussing revolutionary antiviral drugs development and NV-387 efficacy against various viruses NV-387 Antiviral Drugs NanoViricides Inc. Dr. Anil R. Diwan Mission Matters Podcast
Published on 09/25/2026 at 00:30, 1 hour 15 minutes ago Viemed Healthcare Announces Adoption of Automatic Securities Disposition Plan by President Michael Moore
Published on 09/25/2026 at 00:15, 1 hour 30 minutes ago CoTec Holdings Corp. Announces Extension of Private Placement of Unsecured Convertible Debentures
Published on 09/24/2026 at 22:01, 3 hours 44 minutes ago Fermi Selects CBRE to Operate and Maintain Its First Data Center
Published on 09/24/2026 at 14:55, 10 hours 50 minutes ago Nextech3D.ai Surpasses $1 Million in New Customer Contract Value, Expands AI Software Portfolio with KATE and Grows Multi-Year Enterprise Agreements
Published on 09/24/2026 at 20:29, 5 hours 16 minutes ago EQS-Adhoc: HelloFresh SE expects revenue for Q3 2026 below market expectations and adjusts outlook for the financial year 2026
Published on 09/24/2026 at 19:00, 6 hours 45 minutes ago HIAG provides a first-hand insight into its strategy and the added value it generates at its Capital Market Day
Published on 09/24/2026 at 18:40, 7 hours 4 minutes ago EQS-Adhoc: Brockhaus Technologies AG launches public share buyback offer of approx. €90 million for up to 3,592,000 shares
Published on 09/24/2026 at 18:15, 7 hours 30 minutes ago Epanko Value Engineering Identifies 20% Production Increase
Published on 09/24/2026 at 18:05, 7 hours 39 minutes ago DCK Tools Showcases Expanded Outdoor Power Equipment Lineup at Salonvert 2026
Published on 09/24/2026 at 18:31, 7 hours 13 minutes ago LNA SANTE : Mise à disposition du rapport financier semestriel 2026
Published on 09/24/2026 at 18:00, 7 hours 45 minutes ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 7 hours 45 minutes ago GUILLEMOT CORPORATION : Mise à disposition du rapport financier semestriel au 30 juin 2026
